// App-Quantinova.ai

2636 : Anticoagulation Prophylaxis With Enoxaparin For Patients With Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Researchers

Presenter

  • Hassan Sibai

Principal Investigators

  • Jack T Seki

  • Eshetu G Atenafu

  • Karen W.L. Yee

  • Andre C Schuh

  • Vikas Gupta

  • Mark D. Minden

  • Aaron D. Schimmer

  • Joseph M. Brandwein

Medical Centers

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, Ontario Cancer Institute, University of Toronto, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Acute lymphoblastic leukemia

  • Venous thrombosis

  • Pulmonary embolism

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Asparaginase

  • Enoxaparin

  • Enoxaparin sodium

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved